ERBB2 and cancer: A minority of HLA-A2 patients (four of 16; 25%) and of HLA-A26 patients (three of nine; 30%) with HER-2/neu overexpressing cancers in advanced stages had detectable pre-existent CD8+ T-cell responses directed against HER-2(9369) (in all cases, the frequencies ranged between 31.7 and 17.3).